The most common adverse effects with the combination cream are localized reactions such as: erythema (47%), skin discoloration (16%), and edema (14%). Systemic adverse events were less common, occurring at a rate of <1% and included vomiting, headache, dizziness, and fever. Similar to other amide and ester anesthetics, CNS excitation and/or depression may occur. It is not well known at which plasma concentration systemic toxicity occurs with tetracaine; however, the threshold is thought to be much lower than that of lidocaine which is 1000 ng/mL.
Tetracaine is an ester local anaesthetic currently available in combination with lidocaine as a cream and patch.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Tetracaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tetracaine. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Tetracaine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Tetracaine. |
| Hydrocodone | Tetracaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tetracaine. |
| Magnesium sulfate | The therapeutic efficacy of Tetracaine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Tetracaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Tetracaine may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tetracaine. |
| Mirtazapine | Tetracaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Tetracaine. |
| Orphenadrine | Tetracaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Tetracaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Tetracaine. |
| Pramipexole | Tetracaine may increase the sedative activities of Pramipexole. |
| Ropinirole | Tetracaine may increase the sedative activities of Ropinirole. |
| Rotigotine | Tetracaine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Tetracaine. |
| Sodium oxybate | Tetracaine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Tetracaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Tetracaine. |
| Thalidomide | Tetracaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Tetracaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Tetracaine is combined with Prilocaine. |
| Hyaluronidase (ovine) | Hyaluronidase (ovine) can cause an increase in the absorption of Tetracaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Hyaluronidase (human recombinant) | Hyaluronidase (human recombinant) can cause an increase in the absorption of Tetracaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Hyaluronidase | Hyaluronidase can cause an increase in the absorption of Tetracaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Tetracaine. |
| Ethanol | Tetracaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Tetracaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Tetracaine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Tetracaine is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Tetracaine is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Tetracaine is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Tetracaine is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Tetracaine is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Tetracaine is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Tetracaine is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Tetracaine is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Tetracaine is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when Tetracaine is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Tetracaine is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Tetracaine is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Tetracaine is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Tetracaine is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Tetracaine is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Tetracaine is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Tetracaine is combined with Alaproclate. |
| Dapsone | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Tetracaine. |
| Technetium Tc-99m tilmanocept | Tetracaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent. |
| Amitriptyline | The risk or severity of CNS depression can be increased when Amitriptyline is combined with Tetracaine. |
| Olanzapine | The risk or severity of CNS depression can be increased when Olanzapine is combined with Tetracaine. |
| Clozapine | The risk or severity of CNS depression can be increased when Clozapine is combined with Tetracaine. |
| Promazine | The risk or severity of CNS depression can be increased when Promazine is combined with Tetracaine. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Tetracaine. |
| Imipramine | The risk or severity of CNS depression can be increased when Imipramine is combined with Tetracaine. |
| Chlorpromazine | The risk or severity of CNS depression can be increased when Chlorpromazine is combined with Tetracaine. |
| Gallamine triethiodide | The risk or severity of CNS depression can be increased when Gallamine triethiodide is combined with Tetracaine. |
| Triflupromazine | The risk or severity of CNS depression can be increased when Triflupromazine is combined with Tetracaine. |
| Nortriptyline | The risk or severity of CNS depression can be increased when Nortriptyline is combined with Tetracaine. |
| Amoxapine | The risk or severity of CNS depression can be increased when Amoxapine is combined with Tetracaine. |
| Lamotrigine | The risk or severity of methemoglobinemia can be increased when Lamotrigine is combined with Tetracaine. |
| Rocuronium | The risk or severity of CNS depression can be increased when Rocuronium is combined with Tetracaine. |
| Scopolamine | The risk or severity of CNS depression can be increased when Scopolamine is combined with Tetracaine. |
| Clidinium | The risk or severity of CNS depression can be increased when Clidinium is combined with Tetracaine. |
| Propiomazine | The risk or severity of CNS depression can be increased when Propiomazine is combined with Tetracaine. |
| Brompheniramine | The risk or severity of CNS depression can be increased when Brompheniramine is combined with Tetracaine. |
| Flupentixol | The risk or severity of CNS depression can be increased when Flupentixol is combined with Tetracaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Cocaine is combined with Tetracaine. |
| Quinidine | The risk or severity of methemoglobinemia can be increased when Quinidine is combined with Tetracaine. |
| Maprotiline | The risk or severity of CNS depression can be increased when Maprotiline is combined with Tetracaine. |
| Promethazine | The risk or severity of CNS depression can be increased when Promethazine is combined with Tetracaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Diphenhydramine is combined with Tetracaine. |
| Doxacurium | The risk or severity of CNS depression can be increased when Doxacurium is combined with Tetracaine. |
| Doxepin | The risk or severity of CNS depression can be increased when Doxepin is combined with Tetracaine. |
| Desipramine | The risk or severity of CNS depression can be increased when Desipramine is combined with Tetracaine. |
| Quetiapine | The risk or severity of CNS depression can be increased when Quetiapine is combined with Tetracaine. |
| Mivacurium | The risk or severity of CNS depression can be increased when Mivacurium is combined with Tetracaine. |
| Aripiprazole | The risk or severity of CNS depression can be increased when Aripiprazole is combined with Tetracaine. |
| Chlorprothixene | The risk or severity of CNS depression can be increased when Chlorprothixene is combined with Tetracaine. |
| Metocurine | The risk or severity of CNS depression can be increased when Metocurine is combined with Tetracaine. |
| Pancuronium | The risk or severity of CNS depression can be increased when Pancuronium is combined with Tetracaine. |
| Pipecuronium | The risk or severity of CNS depression can be increased when Pipecuronium is combined with Tetracaine. |
| Rapacuronium | The risk or severity of CNS depression can be increased when Rapacuronium is combined with Tetracaine. |
| Pizotifen | The risk or severity of CNS depression can be increased when Pizotifen is combined with Tetracaine. |
| Benactyzine | The risk or severity of CNS depression can be increased when Benactyzine is combined with Tetracaine. |
| Dosulepin | The risk or severity of CNS depression can be increased when Tetracaine is combined with Dosulepin. |
| Emepronium | The risk or severity of CNS depression can be increased when Tetracaine is combined with Emepronium. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Tetracaine. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Tetracaine. |
| Tryptophan | The risk or severity of CNS depression can be increased when Tryptophan is combined with Tetracaine. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of Tetracaine. |
| Lorazepam | The risk or severity of methemoglobinemia can be increased when Lorazepam is combined with Tetracaine. |
| Ethchlorvynol | The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Tetracaine. |
| Succinylcholine | The risk or severity of CNS depression can be increased when Succinylcholine is combined with Tetracaine. |
| Reserpine | The risk or severity of CNS depression can be increased when Reserpine is combined with Tetracaine. |
| Eletriptan | The risk or severity of CNS depression can be increased when Eletriptan is combined with Tetracaine. |
| Temazepam | The risk or severity of CNS depression can be increased when Temazepam is combined with Tetracaine. |
| Reboxetine | The risk or severity of CNS depression can be increased when Reboxetine is combined with Tetracaine. |